Skip to main content
SpringerLink
Log in

Randomized trials in oncology: A fertile ground for controversy

  • Editor’s Commentary
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Emanuel EJ, Patterson WB: Ethics of randomized clinical trials. J Clin Oncol 1998, 16:365–371.

    PubMed  CAS  Google Scholar 

  2. Temple R, Ellenberg SS: Placebo-controlled trials and activecontrol trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Ann Intern Med 2000, 133:455–463.

    PubMed  CAS  Google Scholar 

  3. Ellenberg SS, Temple R: Placebo-controlled trials and activecontrol trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Ann Intern Med 2000, 133:464–470.

    PubMed  CAS  Google Scholar 

  4. Simon R: Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Ann Intern Med 2000, 133:474–475.

    PubMed  CAS  Google Scholar 

  5. Marquis D: How to resolve an ethical dilemma concerning randomized clinical trials. N Engl J Med 1999, 341:691–693.

    Article  PubMed  CAS  Google Scholar 

  6. Hellman D: Evidence, belief, and action: the failure of equipoise to resolve the ethical tension in the randomized clinical trial. J Law Med Ethics 2002, 30:375–380.

    Article  PubMed  Google Scholar 

  7. Pentz RD, Flamm AL, Sugarman J, et al.: Study of the media’s potential influence on prospective research participants’ understanding of and motivations for participation in a high-profile phase I trial. J Clin Oncol 2002, 20:3785–3791.

    Article  PubMed  Google Scholar 

  8. Doyle C, Crump M, Pintilie M, Oza AM: Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001, 19:1266–1274.

    PubMed  CAS  Google Scholar 

  9. Corbie-Smith G, Thomas SB, St. George DMM: Distrust, race, and research. Arch Intern Med 2002, 162:2458–2463.

    Article  PubMed  Google Scholar 

  10. Campos SM, Penson RT, Mays AR, et al.: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001, 81:206–212.

    Article  PubMed  CAS  Google Scholar 

  11. Rose PG, Maxson JH, Fusco N, et al.: Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001, 82:323–328.

    Article  PubMed  CAS  Google Scholar 

  12. Rodriguez M, Rose PG: Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol 2001, 83:257–262.

    Article  PubMed  CAS  Google Scholar 

  13. Bolis G, Scarfone G, Tateo S, et al.: Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel. Gynecol Oncol 2001, 80:13–15.

    Article  PubMed  CAS  Google Scholar 

  14. Schafer A: The ethics of the randomized clinical trial. N Engl J Med 1982, 307:719–724.

    Article  PubMed  CAS  Google Scholar 

  15. Rosner F: The ethics of randomized clinical trials. Am J Med 1987, 82:283–290.

    Article  PubMed  CAS  Google Scholar 

  16. Huston P, Peterson R: Withholding proven treatment in clinical research. N Engl J Med 2001, 345:912–913.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Medical Oncology and the Cancer Center, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    Maurie Markman MD

Authors
  1. Maurie Markman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Randomized trials in oncology: A fertile ground for controversy. Curr Oncol Rep 5, 347–348 (2003). https://doi.org/10.1007/s11912-003-0014-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0014-x

Search

Navigation